
Dr. Zavier Ash Launches New Website to Expand Access to Functional Medicine Services
The new site highlights Dr. Ash's personal approach to holistic healthcare, offering resources for patients seeking alternatives to traditional medicine
Dr. Zavier Ash, a respected physician with over 25 years of experience in both traditional and holistic medicine, is proud to announce the launch of his brand new personal website: https://www.drzavierashgeorgia.com/.
The website is designed to serve as a central .hub for patients and visitors looking to learn more about Dr. Ash's unique approach to functional medicine. Visitors can now access detailed information about his two independent practices: AshCare Functional Medicine, LLC and 7Days Of Weight & Wellness, LLC, both based in Tucker, Georgia.
Dr. Ash has built his career on listening closely to his patients and treating the root causes of illness rather than just the symptoms. The website reflects that philosophy with easy-to-navigate sections that outline services, qualifications, and practical information for new and returning patients.
'My goal was to create a place online where people could truly understand what I do and how I can help,' said Dr. Ash. 'The way we treat health is changing, and I wanted my website to reflect that shift.'
One key feature of the site is information on Dr. Ash's certifications. He is listed on the FMCSA National Registry of Certified Medical Examiners, allowing him to perform DOT physical exams. He is also a USCIS Civil Surgeon serving Dekalb and Gwinnett counties, authorised to conduct immigration physicals.
The site also offers background on Dr. Ash's academic and professional journey, from his early education at Morehouse College to his medical degree from Meharry Medical College, and residencies in OBGYN and family medicine at East Carolina University.
By launching this personal website, Dr. Ash aims to make his services more accessible while also educating the public about the value of functional and integrative healthcare.
About Dr. Zavier Ash
Dr. Zavier Ash is a physician based in Tucker, GA, with more than 25 years of experience in traditional and functional medicine. He is the founder of AshCare Functional Medicine, LLC and 7Days Of Weight & Wellness, LLC. He is FMCSA certified to conduct DOT physicals and is a USCIS Civil Surgeon. Dr. Ash focuses on treating the whole person using a blend of modern medical science and natural remedies.
To read more, visit the website here:
Media Contact
Contact Person: Dr. Zavier Ash
Email: Send Email
City: Tucker
State: GA
Country: United States
Website: https://www.drzavierashgeorgia.com/
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a day ago
- Globe and Mail
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings


Globe and Mail
a day ago
- Globe and Mail
From Scrubs to Coats: Zenir Introduces New White Lab Coat Collection for Healthcare Professionals
Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Torrance, California--(Newsfile Corp. - June 14, 2025) - Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Known for combining functional innovation with elevated style, Zenir continues to raise the standard for medical workwear with this new release. To view an enhanced version of this graphic, please visit: The newly launched white lab coats faithfully embody Zenir's philosophy of comfort, practicality, and refined style. The short-length lab coat is engineered with a three-dimensional pattern that naturally facilitates shoulder and arm movement ideal for dynamic, active roles while the long lab coat features a subtly cinched waistline and matte hidden snap buttons to deliver a sleek, professional silhouette in clinical settings. Meticulously designed storage details, such as a dedicated pen holder in the chest pocket and an inner pocket for smartphones, balance functionality with clean design. Optimized for fast-paced healthcare environments, this collection not only meets workplace requirements but also offers a range of fits and style options to suit every body shape and individual preference. Already recognized for its high-performance scrubs, Zenir is a brand trusted by thousands in the healthcare industry and has sold more than 3 million units globally. The brand has earned its reputation for premium-quality scrubs that are breathable, durable, wrinkle-resistant, and moisture-wicking, now extended to its latest line of white lab coats. As Zenir continues to grow its presence beyond Korea, this expansion into white lab coats marks a milestone in Zenir's commitment to offering a complete spectrum of medical workwear solutions. With thoughtfully tailored cuts, sustainable production using GRS-certified recycled fibers, and a design-first approach, Zenir's new white lab coats are built for professionals who expect more from their daily uniform. For more details, visit


Globe and Mail
a day ago
- Globe and Mail
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. UnitedHealth Group Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. 2. Merck Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025